Indian healthcare start-up ReaGene Innovations has licensed its two Covid-19 diagnostic tests to US-based company Lay Science.
ReaGene developed the ELISA and FAST FLOW SPOT tests to detect the neutralising activity of samples in response to Covid-19 vaccination.
The body develops neutralising antibodies after being vaccinated against the SARS-CoV-2 virus.
These antibodies help fight the virus and provide protection against infections and disease, but decrease after some time, meaning people may require booster doses.
ReaGene’s ELISA diagnostic test is designed to enable the quantitative evaluation of multiple samples at the same time in a hospital or pathology lab setting.
The FAST FLOW SPOT test is a single-user test that can be used by individuals in their homes.
The two diagnostics require an individual’s saliva sample.
ReaGene Innovations scientific co-founder Dr Uday Saxena said: “Collaboration is important as it requires a concerted team effort to fight and win against a virus like Covid-19, the likes of which we have never seen before.
“I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, which will help us in our fight against Covid-19.”
Under the terms of the license deal, Lay Science will pay for the two patent-pending diagnostics’ development through commercialisation.
In addition, the company will make royalty payments to ReaGene after the launch of the two tests.
Lay Science CEO Dr Satish Chandran said: “These saliva-based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defence against the onslaught of rapidly evolving SARS-CoV-2 viral variants.
“These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fight Covid-19.”
ReaGene Innovations is a start-up incubated at ASPIRE BioNEST, the University of Hyderabad’s Incubation centre.